Products Optimized for Outcomes and ROI.

Launched in 2018, Synergy quickly distinguished itself as the Midwest’s premier aesthetics brand for injectables, skincare, and medical devices. Our quality guarantee assures our 1000+ customers will always receive the most cutting-edge products from our extensive network of global manufacturers and partners.

Products optimized for outcomes and ROI

Launched in 2018, Synergy quickly distinguished itself as the Midwest’s premiere aesthetics brand for injectables, skincare, and medical devices. Our quality guarantee assures our 800+ customers that they will always receive the most cutting-edge products from our extensive network of global manufacturers and partners.

Xeomin

Radiesse

Belotero

Neocutis

Ultherapy

Xeomin

Radiesse

Belotero

Neocutis

Ultherapy

Finally, a real skin rejuvenation solution for long-lasting results. The SaltFacial is an exciting, innovative, and non-invasive way to correct and maintain the skin’s natural beauty from head to toe.

How to Build a Successful Subscription-Based Medical Aesthetics Business in 2023

How to Prepare Your Practice For Laser Season

5 Aesthetics Trends for 2023

Our latest Industry Resources.

Want the best minds in aesthetics, in your inbox? Join our email list today.

Ready to get started?

Optimize your products with Synergy.

Our local Synergy AESTHETICS team will help take your practice to the next level using methods that Synergy has developed since our founding in 2018. We are here to support you with clinical product knowledge.

Sign up now and get introduced to your local representative today!

CLICK HERE FOR DISCLAIMER FOR INDICATIONS & USAGE FOR XEOMIN® (incobotulinumtoxinA)

GET IN TOUCH

420 Nichols Rd 2nd Floor

Kansas City, MO 64112

ABOUT

SERVICES

LEGAL

FOLLOW

In the industry? We’re always posting new content that we think you’d love. Give us a follow!

INDICATIONS AND USAGE XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines with corrugator and/or procerus muscle activity in adult patients. IMPORTANT SAFETY INFORMATION WARNING: DISTANT SPREAD OF TOXIN EFFECT See full prescribing information for complete BOXED WARNING.

The effects of XEOMIN® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.

CONTRAINDICATIONS Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur further injection of XEOMIN should be discontinued and appropriate medical therapy immediately instituted. XEOMIN is contraindicated in patients with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation. Use in patients with an infection at the injection site could lead to severe local or disseminated infection. XEOMIN is contraindicated in the presence of infection at the proposed injection site(s).

WARNINGS AND PRECAUTIONS The potency units of XEOMIN® are specific to the preparation and assay method used and are not interchangeable with other preparations of botulinum toxin products. Therefore, Units of biological activity of XEOMIN® cannot be compared to or converted into Units of any other botulinum toxin products. Treatment with XEOMIN ® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. When distant effects occur, additional respiratory muscles may be involved. Patients may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. Dysphagia may persist for several months, which may require use of a feeding tube. Aspiration may result from severe dysphagia [See BOXED WARNING]. Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN®. Glabellar Lines: Do not exceed the recommended dosage and frequency of administration of XEOMIN®. In order to reduce the complication of ptosis the following steps should be taken: avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes; corrugator injections should be placed at least 1 cm above the bony supraorbital ridge. XEOMIN® contains human serum albumin. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and Creutzfeldt-Jakob disease (CJD). No cases of transmission of viral diseases or CJD have ever been reported for albumin. ADVERSE REACTIONS Glabellar Lines: The most commonly observed adverse reaction (incidence ≥ 2% of patients and greater than placebo) for XEOMIN® was Headache (5.4%). DRUG INTERACTIONS Co-administration of XEOMIN® and aminoglycoside antibiotics or other agents interfering with neuromuscular transmission, e.g., tubocurarine-type muscle relaxants, should only be performed with caution as these agents may potentiate the effect of the toxin. Use of anticholinergic drugs after administration of XEOMIN® may potentiate systemic anticholinergic effects. The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. USE IN PREGNANCY There are no adequate data on the developmental risk associated with the use XEOMIN® in pregnant women. XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. PEDIATRIC USE Safety and effectiveness of XEOMIN® in patients less than 18 years of age have not been established.